NIH Awards Grant To Study Dietary Supplement For Prevention Of Prostate Cancer

Irvine, CA – AMC Cancer Research Center (AMC), Denver, has been awarded a two-year grant from the National Institutes of Health (NIH) to study Nexrutine® as a potent prostate cancer preventive agent and to determine the molecular mechanism that underlies its efficacy. Nexrutine is a natural anti-inflammatory ingredient developed by Next Pharmaceuticals for use in dietary supplements. It is a patent-pending plant extract from the bark of Phellodendron trees commonly found in Asia.

Previous studies in the laboratory of Dr. Pratap Kumar at AMC have demonstrated that Nexrutine inhibits the growth of prostate cancer cells through modulation of key components of the cell survival-signaling pathway. Prostate cancer is the most common form of cancer, other than skin cancer, among men in the United States, and it is second only to lung cancer as a cause of cancer-related death among men. The American Cancer Society estimates that in 2003, about 220,900 new cases of prostate cancer will be diagnosed and 28,900 men will die of the disease. The prostate cancer death rate is higher for African-American men than for any other racial or ethnic group. Currently, there are no effective strategies available for its management indicating a need for safe and effective preventive agents. "Obtaining funding from NIH to evaluate the ability of this nutritive supplement using preclinical animal models is timely and we strongly believe that this work will make an important contribution towards the management of prostate cancer," says Dr. Kumar, Principal Investigator on this proposal.

"Dr. Pratap Kumar at AMC has some very exciting preliminary results on the effectiveness of Nexrutine in killing prostate cancer cells," stated Dr. Slaga, Scientific Director of AMC."Because of these results, Dr. Kumar was awarded an NIH grant to further study this patent-pending plant extract.We are very hopeful that Nexrutine will be a safe and effective agent against prostate cancer."

"We are excited about Nexrutine as new approach to maintaining a healthy prostate, in addition to its established safety and efficacy as a natural pain management ingredient," says Bob Garrison, President and CEO of Next Pharmaceuticals. "We believe Nexrutine can play a positive role in cutting health care costs and improving the quality of life."

Next Pharmaceuticals, Inc. is a research and development company that markets its patented or patent-pending ingredients such as Nexrutine to large food, beverage, and dietary supplement companies focused on health enhancement and disease prevention. Nexrutine is a selective COX-2 inhibitor that is the leading natural product for inflammation and pain management. Next has demonstrated that Nexrutine does not cause gastrointestinal (GI) irritation, a common side effect of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. In a two-week human study evaluating the efficacy of Nexrutine to ease soreness in joints and muscles, 72% of the participants said Nexrutine was effective and 86% of the participants said that Nexrutine was gentle on the stomach. Nexrutine is currently under investigation in a placebo-controlled clinical trial to further establish its efficacy.

AMC Cancer Research Center is a not-for-profit research institute dedicated to the prevention of cancer and other chronic diseases. In 1989 AMC became the first institution in the country to devote its scientific resources entirely to the prevention of cancer. Today it has expanded its causation and prevention research into the role of nutrition in the prevention of disease, health communications, behavioral research, and community studies.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.